Glaxosmithkline | GSK - Gross Profit On Sales

Stock Price
60.23
Daily Change
11.94 24.73%
Monthly
23.65%
Yearly
67.12%
Q1 Forecast
50.58

Glaxosmithkline reported GBP8.75B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Bausch Health Companies USD 1.93B 165M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 203.04M 12.04M Sep/2025
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Supernus Pharmaceuticals USD 148.81M 21.01M Sep/2025
Takeda JPY 790.55B 262.97B Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Zoetis USD 1.72B 96M Sep/2025